Cannabinoids: science, risks and German law

Cannabinoids are described through their relationship to the body's cannabinoid system or their chemical relationship to other cannabinoids. The term covers substances with different structures and properties. It does not describe a single effect, one level of risk or a shared legal category, so a claim should always identify the substance concerned.

A statement about a purified molecule is not automatically a statement about an extract containing it. Likewise, a branded mixture is not a new molecule merely because its packaging has a distinctive name. To read a claim critically, ask what was identified, what was tested and whether the tested material matches the material being discussed.

The distinction matters for scientific sources as well. The THCP discovery paper characterises a particular cannabinoid and reports preclinical experiments. It does not validate all products carrying the same abbreviation. A chemical identification can be sound while a broader marketing claim based on it is unsupported.

Origin describes where a substance occurs or how it is produced, not whether it is safe. Endocannabinoids are made within the body; phytocannabinoids occur in plants. Synthetic production makes molecules chemically, while semi-synthetic production chemically modifies an existing starting substance. These descriptions do not establish consumer safety or lawful sale.

A molecule can occur naturally and also be synthesised. THCP illustrates this distinction: finding it in plant material does not establish how a concentrated commercial sample was made. H4CBD illustrates another: using CBD as a starting material does not make the result ordinary CBD. Nor does plant material used as a carrier prove that an added substance originated in that plant.

Start with the chemical distinction you are trying to understand, rather than a ranking of supposed strength. The profiles below separate identity, available research and German legal context. They are informational resources, not recommendations to obtain or use these substances, and they do not offer interchangeable alternatives to one another.

The THCA explainer covers the acidic precursor of THC and why an existing THC result alone can be misleading. The THCP explainer examines the difference between receptor affinity and human effects. The 10-OH-HHC explainer explains why evidence about related molecules cannot settle the properties of a derivative.

The H4CBD explainer distinguishes hydrogenated CBD from CBD itself.

For other plant cannabinoids, read the CBN guide and CBG guide. These names also require substance-specific evidence. The terpenes guide covers a different group of plant compounds: aroma should not be confused with a cannabinoid identity or a demonstrated therapeutic effect.

Research can establish chemical identity, investigate receptor interactions or test biological responses without demonstrating a benefit for people. Each method answers a different question. A receptor assay measures a defined interaction under experimental conditions; it does not measure a person's experience, clinical effectiveness, long-term safety or a safe level of exposure.

In Citti and colleagues' THCP study, receptor findings and animal experiments are preclinical evidence.

They do not establish the familiar claim that THCP is a fixed number of times more intoxicating than THC. In Ben-Shabat and colleagues' work, findings concern hydrogenated CBD-related derivatives, not a clinical evaluation of present-day H4CBD products.

Even a well-conducted experiment has a defined scope. Look for the exact molecule, model and outcome, rather than treating the presence of a scientific reference as an endorsement. Personal accounts cannot close a clinical evidence gap when identity, composition and other exposures are uncertain.

Risk depends both on a substance's properties and on what a sample actually contains. Missing human safety data leave uncertainty about interactions, repeated exposure and vulnerable groups. Unknown mixtures introduce a separate problem: a name on a label does not establish identity, purity or the absence of other active ingredients.

The EUDA overview of semi-synthetic cannabinoids describes a changing market of modified substances and mixtures. This provides context, not a precise adverse-effect rate for every derivative.

Reports involving one substance should not be presented as a proven side-effect profile for another.

A cannabinoid-content test is not automatically a full contaminant screen. A useful report identifies the sample, date, method and tested parameters. Even comprehensive chemical analysis cannot substitute for missing clinical safety evidence.

If severe symptoms, unconsciousness or breathing difficulties occur, call 112. Tell medical staff what the label said and whether other substances might be involved; the label is a clue, not a diagnosis.

As of 1 November 2026, German law does not treat all cannabinoids alike. THCA-rich cannabis flowers generally fall within the KCanG cannabis definition; THCP is covered by NpSG substance-group rules documented since 27 June 2024. H4CBD and 10-OH-HHC require a more cautious assessment, not a statement that they are permitted.

The KCanG definitions distinguish cannabidiol from cannabis, but the exclusion of a molecule does not exempt every product containing it. Plant material, preparations and the particular activity need separate assessment. A claim about cannabis flowers should not be turned into a universal statement about isolated THCA.

The sixth NpSG amendment entered into force on 2 December 2025 and matters for structural assessment. Separately, HHC has been in Annex II BtMG since 23 May 2026. That listing should not be copied automatically to every derivative.

The NpSG uses structural groups, so a trade name need not appear individually for a substance to be covered. This overview is not individual legal advice and does not establish an exemption for a particular sample or transaction.

CBD is a separate subject, not a reassuring label for chemically modified cannabinoids. In Germany, cannabidiol is excluded from the cannabis definition in section 1 KCanG. As of 1 November 2026, that exclusion does not establish that every CBD product can be sold or that it is safe for everyone.

For information about CBD flowers, see the CBD overview. The sale of CBD flowers to consumers is legally disputed in Germany. CBD foods, including oils intended for ingestion, need Novel Food authorisation under Regulation (EU) 2015/2283. A low THC result does not remove these separate requirements.

This section is not a treatment recommendation or a blanket statement of legality.

• THCA explained: research and German law
• THCP explained: evidence and German law
• 10-OH-HHC: research, risks and German law
• H4CBD explained: evidence and German law
• CBN: what cannabinol research really shows
• CBG: cannabigerol chemistry, evidence and law
• Terpenes: cannabis aromas without health promises